ANI Pharmaceuticals Inc (OQ:ANIP)

Feb 20, 2024 06:50 am ET
ANI Pharmaceuticals to Present at the Leerink Partners Global Biopharma Conference
ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that Nikhil Lalwani, Chief Executive Officer, and Stephen Carey, Chief Financial Officer, will present at the Leerink Partners Global Biopharma Conference in Miami Beach...
Feb 07, 2024 06:50 am ET
ANI Pharmaceuticals to Discuss Fourth Quarter and Full Year 2023 Financial Results on February 29, 2024, at 8:30 a.m. ET
ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (NASDAQ: ANIP) today announced that the Company will release its fourth quarter and full year 2023 financial results on Thursday, February 29, 2024, prior to the market open. Nikhil Lalwani,...
Jan 29, 2024 06:50 am ET
ANI Pharmaceuticals to Participate at the Guggenheim Healthcare Talks | 6th Annual Biotechnology Conference
ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that Nikhil Lalwani, Chief Executive Officer, will participate in a fireside chat at the Guggenheim Healthcare Talks | 6th Annual Biotechnology Conference in New York...
Jan 23, 2024 06:50 am ET
ANI Pharmaceuticals Announces the Launch of Pentoxifylline Extended-Release Tablets, USP
ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced the launch of Pentoxifylline Extended-Release (ER) Tablets, USP 400mg. ANI’s Pentoxifylline ER Tablets are the generic version of the Reference Listed Drug (RLD)...
Jan 16, 2024 06:50 am ET
ANI Pharmaceuticals Announces the FDA Approval and Launch of Indomethacin Oral Suspension, USP
ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that it received U.S. Food and Drug Administration (FDA) approval for the Abbreviated New Drug Application (ANDA) for Indomethacin Oral Suspension (OS), USP. ANI’s...
Nov 22, 2023 09:26 am ET
ANI Pharmaceuticals to Present at the Piper Sandler 35th Annual Healthcare Conference
ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that Nikhil Lalwani, President & CEO, will participate at the Piper Sandler 35th Annual Healthcare Conference in New York City as follows: Date:    Tuesday, November...
Nov 08, 2023 06:50 am ET
ANI Pharmaceuticals Reports Record Third Quarter 2023 Financial Results and Raises Full-Year 2023 Guidance
ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) (ANI or the Company) today announced business highlights and financial results for the three months ended September 30, 2023. Nikhil Lalwani, President and CEO of ANI stated, “Strong execution has resulted...
Oct 30, 2023 06:50 am ET
ANI Pharmaceuticals to Participate at Two Upcoming Healthcare Conferences
ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that Nikhil Lalwani, Chief Executive Officer, and Stephen Carey, Chief Financial Officer, will participate at two upcoming healthcare conferences as follows: Truist...
Oct 25, 2023 06:50 am ET
ANI Pharmaceuticals to Discuss Third Quarter 2023 Financial Results on November 8, 2023, at 8:30 a.m. ET
ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (NASDAQ: ANIP) today announced that the Company will release its third quarter 2023 financial results on Wednesday, November 8, 2023, prior to the market open. Nikhil Lalwani, President and...
Oct 02, 2023 06:50 am ET
ANI Pharmaceuticals Announces FDA Approval and Commercial Availability of New 1-mL Vial Size of Purified Cortrophin® Gel, Appropriate for Adjunctive Treatment of Certain Patients with Acute Gouty Art
ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced U.S. Food and Drug Administration (FDA) approval and commercial availability of a 1-mL vial (80 USP units/1 mL) of Purified Cortrophin® Gel (repository corticotropin...
Sep 18, 2023 04:05 pm ET
ANI Pharmaceuticals to Present at the Cantor Global Healthcare Conference 2023
ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that Nikhil Lalwani, Chief Executive Officer, and Stephen Carey, Chief Financial Officer, will present at the Cantor Global Healthcare Conference 2023 in New York City as...
Sep 12, 2023 06:50 am ET
ANI Pharmaceuticals Announces the FDA Approval and Launch of Estradiol Tablets USP
ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that it received U.S. Food and Drug Administration (FDA) approval for the Abbreviated New Drug Application (ANDA) for Estradiol Tablets USP. ANI’s Estradiol Tablets...
Aug 28, 2023 06:50 am ET
ANI Pharmaceuticals Announces the FDA Approval and Launch of Estradiol Gel, 0.1%
ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that it received U.S. Food and Drug Administration (FDA) approval for the Abbreviated New Drug Application (ANDA) for Estradiol Gel, 0.1%. ANI’s Estradiol Gel, 0.1%, is...
Aug 24, 2023 06:50 am ET
ANI Pharmaceuticals to Present at the H.C. Wainwright 25th Annual Global Investment Conference
ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that Nikhil Lalwani, Chief Executive Officer, and Stephen Carey, Chief Financial Officer, will present at the H.C. Wainwright 25th Annual Global Investment Conference in...
Aug 23, 2023 06:50 am ET
ANI Pharmaceuticals Appoints Healthcare Executive Matthew J. Leonard to its Board of Directors
ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced the addition of Matthew J. Leonard, R.Ph. to its Board of Directors. Mr. Leonard brings more than 35 years of experience as an accomplished leader and innovator within...
Aug 09, 2023 06:50 am ET
ANI Pharmaceuticals Reports Record Second Quarter 2023 Financial Results and Raises Full-Year 2023 Guidance  
ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) (ANI or the Company) today announced business highlights and financial results for the three months ended June 30, 2023. “The second quarter of 2023 was another strong quarter for ANI, across all areas of...
Jul 31, 2023 07:17 am ET
ANI Pharmaceuticals to Discuss Second Quarter 2023 Financial Results on August 9, 2023, at 8:30 a.m. ET
ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (NASDAQ: ANIP) today announced that the Company will release its second quarter 2023 financial results on Wednesday, August 9, 2023, prior to the market open. Nikhil Lalwani, President and Chief...
May 22, 2023 06:34 pm ET
ANI Pharmaceuticals to Present at the Jefferies Healthcare Conference
ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that Nikhil Lalwani, Chief Executive Officer, and Stephen Carey, Chief Financial Officer, will present at the Jefferies Healthcare Conference in New York City as follows:
May 16, 2023 04:05 pm ET
ANI Pharmaceuticals Announces Closing of Public Offering of Common Stock Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) (“ANI” or the “Company”) today announced the closing of its previously announced underwritten public offering. A total of 2,183,545 shares of its common stock were sold at a public offering price of $39.50 per share, inclusive of the exercise in full of the underwriters’ option to purchase an additional 284,810 shares of common stock. The gross proceeds of the offering to the Company are approximately $86.25 million, before deducting the underwriting discounts and commissions and offering expenses.
May 15, 2023 06:50 am ET
ANI Pharmaceuticals Announces FDA Approval and Commercialization of Two ANDAs with CGT Exclusivity
ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that it received U.S. Food and Drug Administration (FDA) approval for the Abbreviated New Drug Applications (ANDAs) for Methsuximide Capsules USP, 300 mg and Alendronate Sodium Oral Solution 70 mg (base)/75 mL. Methsuximide Capsules has been granted 180-day Competitive Generic Therapy (CGT) Exclusivity, and Alendronate Sodium Oral Solution is eligible for CGT Exclusivity upon launch.
May 12, 2023 07:03 am ET
ANI Pharmaceuticals Announces Pricing of $75 Million Public Offering of Common Stock
ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) (“ANI” or the "Company") today announced the pricing of its previously announced underwritten public offering of 1,898,735 shares of its common stock at a public offering price of $39.50 per share. The gross proceeds of the offering to the Company are expected to be $75 million, before deducting the underwriting discounts and commissions and other offering expenses. In addition, ANI granted the underwriters a 30-day option to purchase up to an additional 284,810 shares of common stock at the public offering price, less underwriting discounts and commiss
May 11, 2023 04:01 pm ET
ANI Pharmaceuticals Announces Proposed Public Offering of Common Stock
ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) (“ANI”) today announced that it intends to offer and sell shares of its common stock in an underwritten public offering. All of the shares to be sold in the offering will be offered by ANI. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. In addition, ANI intends to grant the underwriters a 30-day option to purchase up to an additional 15% of shares of its common stock offered in the public offering.
May 08, 2023 06:50 am ET
ANI Pharmaceuticals Reports Record First Quarter 2023 Financial Results and Raises Full-Year 2023 Guidance
ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) (ANI or the Company) today announced business highlights and financial results for the three months ended March 31, 2023.
Apr 27, 2023 06:50 am ET
ANI Pharmaceuticals to Discuss First Quarter 2023 Financial Results on May 8, 2023, at 8:30 a.m. ET
ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (NASDAQ: ANIP) today announced that the Company will release its first quarter 2023 financial results on Monday, May 8, 2023, prior to the market open.
Apr 26, 2023 04:15 pm ET
ANI Pharmaceuticals to Present at the H.C. Wainwright BioConnect Investor Conference at NASDAQ
ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that Nikhil Lalwani, Chief Executive Officer, and Stephen Carey, Chief Financial Officer, will present at the H.C. Wainwright BioConnect Investor Conference at the NASDAQ Headquarters in New York City as follows:
Apr 24, 2023 06:50 am ET
ANI Pharmaceuticals Announces the FDA Approval and Launch of Nitrofurantoin Oral Suspension USP
ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that it received U.S. Food and Drug Administration (FDA) approval for the Abbreviated New Drug Application (ANDA) for Nitrofurantoin Oral Suspension USP, 25 mg/5 ml.
Apr 04, 2023 06:50 am ET
ANI Pharmaceuticals Announces the FDA Approval of Colestipol Hydrochloride Tablets USP
ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that it received U.S. Food and Drug Administration (FDA) approval for the Abbreviated New Drug Application (ANDA) for Colestipol Hydrochloride Tablets USP, 1 g.
Mar 09, 2023 06:50 am ET
ANI Pharmaceuticals Reports Record Fourth Quarter Financial Results and Achieves Full Year 2022 Revenue Milestone; Initiates 2023 Guidance
ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) (ANI or the Company) today announced business highlights and financial results for the three and 12 months ended December 31, 2022.
Feb 22, 2023 04:05 pm ET
ANI Pharmaceuticals to Discuss Fourth Quarter and Full Year 2022 Financial Results on March 9, 2023, at 8:30 a.m. ET
ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (NASDAQ: ANIP) today announced that the Company will release its fourth quarter and full year 2022 financial results on Thursday, March 9, 2023, prior to market open.
Dec 19, 2022 04:56 pm ET
ANI Pharmaceuticals Announces the FDA Approval and Launch of Levocarnitine Tablets USP
ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that it received U.S. Food and Drug Administration (FDA) approval for the Abbreviated New Drug Application (ANDA) for Levocarnitine Tablets USP, 330 mg.
Nov 28, 2022 06:50 am ET
ANI Pharmaceuticals Announces the FDA Approval and Launch of Fluoxetine Oral Solution USP
ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (Nasdaq: ANIP) today announced that the Company received U.S. Food and Drug Administration (FDA) approval for the Abbreviated New Drug Application (ANDA) for Fluoxetine Oral Solution, USP 20 mg/5 mL.
Nov 16, 2022 06:50 am ET
ANI Pharmaceuticals Announces the FDA Approval and Launch of Trimethoprim Tablets USP
ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that it received U.S. Food and Drug Administration (FDA) approval for the Abbreviated New Drug Application (ANDA) for Trimethoprim Tablets USP, 100 mg.
Nov 09, 2022 06:50 am ET
ANI Pharmaceuticals Reports Third Quarter 2022 Financial Results; Reports Record Net Revenues
ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) (ANI or the Company) today announced business highlights and financial results for the three and nine months ended September 30, 2022.
Oct 24, 2022 06:50 am ET
ANI Pharmaceuticals to Discuss Third Quarter 2022 Financial Results on November 9, 2022, at 8:00 a.m. ET
ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (NASDAQ: ANIP) today announced that the Company will release its third quarter 2022 financial results on Wednesday, November 9, 2022, prior to market open.
Sep 12, 2022 06:50 am ET
ANI Pharmaceuticals Appoints Krista Davis as Chief Human Resources Officer
ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) (“ANI” or the “Company”) today announced that Krista L. Davis will join the Company as Chief Human Resources Officer, effective September 12. Ms. Davis brings to the Company over 20 years of executive leadership experience in human resources, talent management, and organizational developm
Aug 30, 2022 04:05 pm ET
ANI Pharmaceuticals to Present at the H.C. Wainwright 24th Annual Global Investment Conference
ANI Pharmaceuticals, Inc. (“ANI” or “the Company”) (Nasdaq: ANIP) today announced that Nikhil Lalwani, Chief Executive Officer, and Stephen Carey, Chief Financial Officer, will present at the H.C. Wainwright 24th Annual Global Investment Conference as follows:
Aug 29, 2022 06:50 am ET
ANI Pharmaceuticals Announces the Launch of Prochlorperazine Maleate Tablets USP
ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (Nasdaq: ANIP) today announced the launch of Prochlorperazine Maleate Tablets USP, 5 mg and 10 mg.
Aug 16, 2022 06:50 am ET
ANI Pharmaceuticals Announces FDA Approval and Imminent Launch of Dexamethasone Tablets USP
ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that the Company received U.S. Food and Drug Administration (FDA) approval for the Abbreviated New Drug Application (ANDA) for Dexamethasone Tablets USP 1.5mg, 4mg and 6mg.
Aug 08, 2022 06:50 am ET
ANI Pharmaceuticals Reports Second Quarter 2022 Financial Results; Reports Record Net Revenues and Raises Full-Year 2022 Net Revenue Guidance for Purified Cortrophin® Gel
ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) (ANI or the Company) today announced business highlights and financial results for the three and six months ended June 30, 2022.
Aug 03, 2022 06:50 am ET
ANI Pharmaceuticals Announces the Launch of Acebutolol Hydrochloride Capsules USP
ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (Nasdaq: ANIP) today announced the launch of Acebutolol Hydrochloride Capsules.
Jul 28, 2022 06:50 am ET
ANI Pharmaceuticals Acquires ANDAs from Oakrum Pharma, LLC
“We are pleased to expand our generics product portfolio with the acquisition of four limited competition ANDAs. We expect to launch these products and see the value unlock in 2023. This transaction bears further testament to ANI’s strength in business development and complements the significant investment and efforts of our internal research and development team to bring much-needed medicines to patients in need,” stated Nikhil Lalwani, President and Chief Executive Officer of ANI.
Jul 25, 2022 04:05 pm ET
ANI Pharmaceuticals to Discuss Second Quarter 2022 Financial Results on August 8, 2022, at 8:00 a.m. ET
ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (NASDAQ: ANIP) today announced that the Company will release its second quarter 2022 financial results on Monday, August 8, 2022, prior to market open.
Jul 18, 2022 06:50 am ET
ANI Pharmaceuticals Appoints Meredith W. Cook as SVP, General Counsel and Corporate Secretary
ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) (ANI or the Company) today announced that Meredith W. Cook will join the Company as SVP, General Counsel and Corporate Secretary, effective July 18. Ms. Cook brings over 20 years of legal and leadership experience in specialty and generics pharmaceuticals, including in corporate governanc
Jun 22, 2022 06:50 am ET
ANI Pharmaceuticals Announces FDA Approval and Imminent Launch of Clorazepate Dipotassium Tablets USP
ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that the Company received U.S. Food and Drug Administration (FDA) approval for the Abbreviated New Drug Application (ANDA) for Clorazepate Dipotassium Tablets.
Jun 21, 2022 07:03 am ET
ANI Pharmaceuticals Adopts Veeva Commercial Cloud to Better Support Rare Disease Patients
Partnership drives commercial excellence through precision engagement to benefit patients in need of options
Jun 02, 2022 04:05 pm ET
ANI Pharmaceuticals Announces Consolidation of Manufacturing Network, Capturing Operational Synergies Post Novitium Acquisition
ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) (ANI or the Company) today announced that it intends to cease operations at its Oakville, Ontario, Canada manufacturing plant by first quarter 2023. This action is part of ongoing initiatives to capture operational synergies following the Company’s acquisition of Novitium Pharma in November 2021.
Jun 01, 2022 04:15 pm ET
ANI Pharmaceuticals Announces the FDA Approval and Imminent Launch of Fludrocortisone Acetate Tablets USP
ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (Nasdaq: ANIP) today announced that the Company received U.S. Food and Drug Administration (“FDA”) approval for the Abbreviated New Drug Application (ANDA) for Fludrocortisone Acetate Tablets USP, 0.1 mg.
May 20, 2022 06:50 am ET
ANI Pharmaceuticals to Present at Upcoming Healthcare Investor Conferences
ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that Nikhil Lalwani, Chief Executive Officer, and Stephen Carey, Chief Financial Officer, will present at two upcoming conferences as follows:
May 10, 2022 06:50 am ET
ANI Pharmaceuticals Reports First Quarter 2022 Results; Provides Purified Cortrophin® Gel Net Revenue Guidance and Full-Year 2022 Total Company Net Revenue Guidance of $295 Million to $315 Million
ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) (ANI or the Company) today announced business highlights and financial results for the three months ended March 31, 2022.
Apr 19, 2022 06:50 am ET
ANI Pharmaceuticals to Discuss First Quarter 2022 Financial Results on May 10, 2022
ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (NASDAQ: ANIP) today announced that the Company will release its first quarter 2022 financial results on Tuesday, May 10, 2022.
Apr 11, 2022 06:50 am ET
ANI Pharmaceuticals Announces the Launch of Misoprostol Tablets
ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (Nasdaq: ANIP) today announced the launch of Misoprostol Tablets, 100 mcg and 200 mcg.
Mar 22, 2022 04:05 pm ET
ANI Pharmaceuticals Appoints Experienced Commercial Leader, Renee P. Tannenbaum, Pharm.D., MBA, to Board of Directors
ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) (ANI or the Company) today announced the addition of Renee P. Tannenbaum, Pharm.D., MBA, to its Board of Directors. Dr. Tannenbaum has over 35 years of management experience in the pharmaceutical industry. This appointment is effective immediately and increases ANI’s Board of Directors to
Mar 15, 2022 06:50 am ET
ANI Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Results; Strong Foundation in Place to Drive Sustainable Growth
ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) (ANI or the Company) today announced business highlights and financial results for the three and twelve months ended December 31, 2021.
Mar 07, 2022 06:50 am ET
ANI Pharmaceuticals to Discuss Fourth Quarter and Full Year 2021 Financial Results on March 15, 2022
Nikhil Lalwani, President and Chief Executive Officer, and Stephen P. Carey, Senior Vice President, Finance, and Chief Financial Officer, will host a conference call to discuss the results as follows:
Feb 24, 2022 06:50 am ET
ANI Pharmaceuticals Strengthens Rare Disease Business Unit Leadership Team
ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) (ANI or the Company) today announced two additions to its Rare Disease Business Unit leadership team. Mary Pao, M.D., Ph.D., has been appointed Chief Medical Officer, and Elizabeth Powell, J.D., has been appointed Chief Compliance Officer and Head of Legal. These appointments build on the
Feb 14, 2022 04:00 pm ET
Oakrum Pharma and ANI Pharmaceuticals Announce the Launch of Betaine Anhydrous Powder, the first Generic Version of Cystadane® (betaine anhydrous for oral solution) Powder, Including 180 Days of Excl
SAINT LOUIS, Feb. 14, 2022 /PRNewswire/ -- Oakrum Pharma, LLC ("Oakrum Pharma"), in collaboration with ANI Pharmaceuticals (NASDAQ: ANIP), announce that the U.S. Food and Drug Administration (FDA) has approved the Abbreviated New Drug Application (ANDA) for a generic version of Cystadane®1 (betaine anhydrous for oral solution) Powder in a 180 gm bottle and granted Competitive Generic Therapy (CGT) of 180 days of exclusivity.  Shipments of the generic product began in early February, 2022.
Jan 24, 2022 06:50 am ET
ANI Pharmaceuticals Announces Commercial Availability of Purified Cortrophin™ Gel (Repository Corticotropin Injection USP) for Multiple Chronic Autoimmune Disorders
ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) (ANI or the Company) today announced the U.S. commercial availability of Purified Cortrophin™ Gel (Repository Corticotropin Injection USP) 80 U/mL. The commercial launch of Cortrophin Gel, an adrenocorticotropic hormone (ACTH), also known as purified corticotropin, is being led by ANI’s r
Jan 03, 2022 04:30 pm ET
ANI Pharmaceuticals to Present at the H.C. Wainwright Bioconnect Virtual Conference
ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that Nikhil Lalwani, Chief Executive Officer, and Stephen Carey, Chief Financial Officer, will present virtually at the H.C. Wainwright Bioconnect Conference as follows:
Dec 21, 2021 06:50 am ET
ANI Pharmaceuticals Announces FDA Approval and Imminent Launch of Rifabutin Capsules USP
ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (Nasdaq: ANIP) today announced that the Company received U.S. Food and Drug Administration (“FDA”) approval for the Abbreviated New Drug Application for Rifabutin Capsules USP, 150 mg.
Dec 20, 2021 07:30 am ET
Eton Pharmaceuticals and ANI Pharmaceuticals Announce Commercial Availability of Carglumic Acid Tablets, the First and Only FDA-Approved Generic Version of Carbaglu® (carglumic acid)
Eton Pharmaceuticals, Inc (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases and ANI Pharmaceuticals, Inc (Nasdaq: ANIP), a bio-pharmaceutical company serving patients in need...
Nov 22, 2021 06:50 am ET
ANI Pharmaceuticals Completes Acquisition of Novitium Pharma, Significantly Enhancing R&D Capabilities and Scale of Generics and CDMO Businesses
ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) (ANI or the Company) today announced that it has completed the previously announced acquisition of Novitium Pharma, a privately held, New Jersey-based pharmaceutical company with development, manufacturing, and commercialization capabilities.
Nov 22, 2021 06:40 am ET
ANI Pharmaceuticals to Present at the Piper Sandler 33rd Annual Healthcare Conference 2021
ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (Nasdaq: ANIP) today announced that Nikhil Lalwani, Chief Executive Officer, and Stephen Carey, Chief Financial Officer, will present virtually at the Piper Sandler 33rd Annual Healthcare Conference 2021 as follows:
Nov 11, 2021 06:50 am ET
ANI Pharmaceuticals Receives Clearance from U.S. Federal Trade Commission for the Acquisition of Novitium Pharma
ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) (ANI or the Company) today announced that the U.S. Federal Trade Commission (the FTC) has accepted the proposed consent order in connection with ANI's definitive agreement to acquire Novitium Pharma. The divestitures required by the FTC of development rights to one generic drug and assets with respect to another generic drug are immaterial to the Company’s business.
Nov 08, 2021 04:05 pm ET
ANI Pharmaceuticals, Inc. Announces Closing of $75 Million Public Offering of Common Stock
ANI Pharmaceuticals, Inc. (NASDAQ: ANIP) (ANI or the Company) today announced the closing of its previously announced underwritten public offering. A total of 1,500,000 shares of its common stock were sold at a public offering price of $50.00 per share. The gross proceeds of the offering to the Company are $75 million, before deducting the underwriting discounts and commissions and offering expenses. In addition, ANI granted the underwriters a 30-day option to purchase up to an additional 225,000 shares of common stock at the public offering price, less underwriting discounts and commissions.
Nov 03, 2021 10:54 pm ET
ANI Pharmaceuticals, Inc. Announces Pricing of $75 Million Public Offering of Common Stock
ANI Pharmaceuticals, Inc. (NASDAQ: ANIP) (“ANI” or the "Company") today announced the pricing of an underwritten public offering of 1,500,000 shares of its common stock at a public offering price of $50.00 per share. The gross proceeds of the offering to the Company are expected to be $75 million, before deducting the underwriting discounts and commissions and other offering expenses. In addition, ANI granted the underwriters a 30-day option to purchase up to an additional 225,000 shares of common stock at the public offering price, less underwriting discounts and commissions.
Nov 03, 2021 04:03 pm ET
ANI Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock
ANI Pharmaceuticals, Inc. (NASDAQ: ANIP) (“ANI”) today announced that it intends to offer and sell shares of its common stock in an underwritten public offering. All of the shares to be sold in the offering will be offered by ANI. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. In addition, ANI intends to grant the underwriters a 30-day option to purchase up to an additional 15% of shares of its common stock offered in the public offering.
Nov 01, 2021 06:45 am ET
ANI Pharmaceuticals Reports Third Quarter 2021 Results
ANI Pharmaceuticals, Inc. (ANI or the Company) (NASDAQ: ANIP) today announced business highlights and financial results for the three months ended September 30, 2021.
Nov 01, 2021 06:30 am ET
ANI Pharmaceuticals Announces FDA Approval of Purified Cortrophin™ Gel for Multiple Indications Including Multiple Sclerosis, Rheumatoid Arthritis and Nephrotic Syndrome
ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) (ANI or the Company) today announced that the U.S. Food and Drug Administration (FDA) has approved the Company’s supplemental New Drug Application (sNDA) for Purified Cortrophin™ Gel (Repository Corticotropin Injection USP) (Cortrophin Gel) for the treatment of certain chronic autoimmune disorders, including acute exacerbations of multiple sclerosis (MS) and rheumatoid arthritis (RA), in addition to excess urinary protein due to nephrotic syndrome. Cortrophin Gel is an adrenocorticotropic hormone (ACTH), also known as purified corticotropin.
Oct 29, 2021 04:30 pm ET
ANI Pharmaceuticals to Discuss Third Quarter 2021 Financial Results on November 1, 2021
ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (NASDAQ: ANIP) today announced that the Company will release its third quarter 2021 financial results on Monday, November 1, 2021.
Sep 20, 2021 04:30 pm ET
ANI Pharmaceuticals to Present at Cantor Virtual Global Healthcare Conference 2021
ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (Nasdaq: ANIP) today announced that Nikhil Lalwani, Chief Executive Officer, and Stephen Carey, Chief Financial Officer, will present at the Cantor Virtual Global Healthcare Conference 2021 as follows:
Sep 17, 2021 06:50 am ET
ANI Pharmaceuticals Announces Launch of Nebivolol Tablets
ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (Nasdaq: ANIP) today announced the launch of Nebivolol Tablets, 2.5 mg, 5 mg, 10 mg, and 20 mg.
Aug 31, 2021 06:50 am ET
ANI Pharmaceuticals Announces FDA Acceptance of Purified Cortrophin® Gel Supplemental New Drug Application for Multiple Indications Including Multiple Sclerosis, Rheumatoid Arthritis, and Nephrotic Sy
ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (Nasdaq:ANIP) today announced that the Company’s supplemental New Drug Application (“sNDA”) for Purified Cortrophin® Gel (“Cortrophin Gel”) has been accepted by the U.S. Food and Drug Administration (“FDA”) for review.
Aug 06, 2021 07:24 am ET
ANI Pharmaceuticals Reports Second Quarter 2021 Results
ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (NASDAQ: ANIP) today announced business highlights and financial results for the three and six months ended June 30, 2021.
Jul 22, 2021 04:30 pm ET
ANI Pharmaceuticals to Discuss Second Quarter 2021 Financial Results on August 6, 2021
ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (NASDAQ: ANIP) today announced that the Company will release its second quarter 2021 financial results on Friday, August 6, 2021.
Jul 06, 2021 06:50 am ET
ANI Pharmaceuticals Announces Refiling of Cortrophin sNDA with FDA
ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (Nasdaq: ANIP) today announced that the Company has re-filed its supplemental new drug application (“sNDA”) for Cortrophin® Gel with the U.S. Food and Drug Administration (“FDA”).
Jun 15, 2021 04:05 pm ET
ANI Pharmaceuticals to Present at the Raymond James Human Health Innovation Conference 2021
ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (Nasdaq: ANIP) today announced that Nikhil Lalwani, Chief Executive Officer, and Stephen Carey, Chief Financial Officer, will present at the Raymond James Human Health Innovation Conference 2021 as follows:
Jun 01, 2021 04:05 pm ET
ANI Pharmaceuticals Announces Details of 2021 Virtual Annual Meeting of Stockholders
ANI Pharmaceuticals, Inc. (“ANI“ or the “Company“) (Nasdaq: ANIP) today announced log-in details for its 2021 Virtual Annual Meeting of Stockholders to be held on June 2, 2021, beginning at 10 a.m. Eastern Time.
May 27, 2021 04:30 pm ET
ANI Pharmaceuticals to Present at Jefferies Virtual Healthcare Conference 2021
ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (Nasdaq: ANIP) today announced that Nikhil Lalwani, Chief Executive Officer, and Stephen Carey, Chief Financial Officer, will present at the Jefferies Virtual Healthcare Conference 2021 as follows:
May 07, 2021 06:50 am ET
ANI Pharmaceuticals Reports First Quarter 2021 Results
ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (NASDAQ: ANIP) today announced business highlights and financial results for the three months ended March 31, 2021.
Apr 26, 2021 04:30 pm ET
ANI Pharmaceuticals to Discuss First Quarter 2021 Financial Results on May 7, 2021
ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (NASDAQ: ANIP) today announced that the Company will release its first quarter 2021 financial results on Friday, May 7, 2021.
Apr 06, 2021 06:50 am ET
ANI Pharmaceuticals Expands Branded Products Portfolio Through Acquisition of Sandoz Inc. NDAs
ANI Pharmaceuticals, Inc. (“ANI”) (NASDAQ:ANIP) today announced that it has acquired the new drug applications (“NDAs”) for OXISTAT® Lotion, VEREGEN® Ointment, and Pandel® Cream and the abbreviated new drug application (“ANDA”) for ApexiCon® E Cream from Sandoz Inc. Pandel® Cream will be transitioned later upon receiving the requisite approvals. Collectively, these products generated net revenues of $13.2 million in 2020. The acquisition was funded through borrowings under the Company’s pre-existing revolver credit facility.
Mar 09, 2021 06:50 am ET
ANI Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Results; Company Positioned for Sustainable Future Growth
ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (NASDAQ: ANIP) today announced business highlights and financial results for the three and 12 months ended December 31, 2020.
Mar 09, 2021 06:45 am ET
ANI Pharmaceuticals to Acquire Novitium Pharma, Strengthening R&D Engine and Expanding Generics and CDMO Business
ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (Nasdaq: ANIP) today announced that it has signed a definitive agreement to acquire Novitium Pharma, a privately held, New Jersey-based pharmaceutical company with development, manufacturing, and commercialization capabilities for $163.5 million, including $89.5 million in cash and $74 million in equity plus two potential future cash earn-outs of up to $46.5 million. The transaction has been approved by the ANI Board of Directors and is expected to close in the second half of 2021, subject to regulatory approvals and approval by ANI shareholde
Feb 19, 2021 04:30 pm ET
ANI Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
ANI Pharmaceuticals, Inc. (“ANI“ or the “Company“) (Nasdaq: ANIP) today announced that ANI's Board of Directors granted non-qualified inducement stock options to purchase an aggregate of 27,006 shares of ANI's common stock to Ori Gutwerg, ANI’s Senior Vice President, Generics, and an aggregate of 33,758 shares to Christopher Mutz, ANI’s Chief Commercial Officer & Head of Rare Disease, effective February 15, 2021.
Feb 17, 2021 06:50 am ET
ANI Pharmaceuticals Strengthens Leadership Team to Accelerate Future Growth
ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (Nasdaq: ANIP) today announced the addition of three key pharmaceutical executives: Christopher K. Mutz as Chief Commercial Officer and Head of Rare Diseases; Ori Gutwerg as Senior Vice President of Generics; and Davinder Singh as General Manager, Canadian Operations.
Feb 16, 2021 04:30 pm ET
ANI Pharmaceuticals to Discuss Fourth Quarter and Full Year 2020 Financial Results on March 9, 2021
ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (NASDAQ: ANIP) today announced that the Company will release its fourth quarter and full year 2020 financial results on Tuesday, March 9, 2021.
Feb 01, 2021 06:50 am ET
ANI Pharmaceuticals Announces Launch of Prazosin Hydrochloride (“HCl”) Capsules
ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (Nasdaq: ANIP) today announced the launch of Prazosin HCl Capsules USP, 1mg and 2mg, following the U.S. Food and Drug Administration’s (“FDA”) approval of the Company’s prior approval supplement application (“PAS”).
Dec 17, 2020 06:50 am ET
ANI Pharmaceuticals Announces Approval and Launch of Aminocaproic Acid Tablets
ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (Nasdaq: ANIP) today announced U.S. Food and Drug Administration (FDA) approval and the launch of Aminocaproic Acid Tablets USP, 500mg. The current annual U.S. market for this product is approximately $12.7 million, according to IQVIA/IMS Health.
Nov 05, 2020 06:50 am ET
ANI Pharmaceuticals Reports Third Quarter 2020 Results
ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (NASDAQ: ANIP) today announced business highlights and financial results for the three and nine months ended September 30, 2020.
Oct 29, 2020 06:50 am ET
ANI Pharmaceuticals Schedules Conference Call to Discuss Third Quarter 2020 Financial Results
ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (NASDAQ: ANIP) today announced that the Company will release its third quarter 2020 financial results on Thursday, November 5, 2020, before the opening of the U.S. financial markets.
Sep 10, 2020 07:00 pm ET
ANI Pharmaceuticals Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (Nasdaq: ANIP) today announced that the Compensation Committee of ANI’s Board of Directors granted a non-qualified inducement stock option to purchase an aggregate of 179,643 shares of ANI’s common stock to Nikhil Lalwani, President and Chief Executive Officer of ANI, effective September 8, 2020.
Aug 06, 2020 06:50 am ET
ANI Pharmaceuticals Reports Second Quarter 2020 Results
ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (NASDAQ: ANIP) today announced business highlights and financial results for the three and six months ended June 30, 2020.
Aug 06, 2020 06:45 am ET
ANI Pharmaceuticals Appoints Experienced Pharmaceutical Executives, Jeanne Thoma and Antonio “Tony” Pera to Board of Directors
ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (Nasdaq:ANIP) today announced the appointments of Jeanne Thoma, President and Chief Executive Officer of SPI Pharma, Inc. and Antonio (“Tony”) Pera, former President of Par Pharmaceutical to the ANI Pharmaceuticals Board of Directors. These appointments are effective immediately and increase ANI’s Board of Directors to seven members, including Nikhil Lalwani, who will join the Board next month when he starts as President and CEO of the Company on September 8, 2020.
Aug 03, 2020 06:50 am ET
ANI Pharmaceuticals Names Nikhil Lalwani as President and Chief Executive Officer
“We are delighted to welcome Nikhil to ANI Pharmaceuticals. With his proven ability to create high-growth cultures and deliver financial results, together with his operational experience in both generics and specialty pharmaceuticals, Nikhil is an ideal choice to lead our next phase of growth and to achieve our corporate objectives,” stated Patrick Walsh, Interim President and Chief Executive Officer of ANI Pharmaceuticals.
Jul 30, 2020 06:50 am ET
ANI Pharmaceuticals Schedules Conference Call to Discuss Second Quarter 2020 Financial Results
ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (NASDAQ: ANIP) today announced that the Company will release its second quarter 2020 financial results on Thursday, August 6, 2020, before the opening of the U.S. financial markets.
Jul 06, 2020 08:30 am ET
ANI Pharmaceuticals Announces Acquisition of Fluconazole Tablets
BAUDETTE, Minn., July 6, 2020 /PRNewswire/ -- ANI Pharmaceuticals, Inc. ("ANI") (Nasdaq: ANIP) today announced the acquisition of Fluconazole Tablets USP, 50mg, 100mg, 150mg, and 200mg from a private company for $3.0 million.  The current annual U.S. market for this product is approximately $40 million, according to IQVIA/IMS Health.
Jun 30, 2020 08:30 am ET
ANI Pharmaceuticals Announces Launch of Mexiletine Hydrochloride Capsules
BAUDETTE, Minn., June 30, 2020 /PRNewswire/ -- ANI Pharmaceuticals, Inc. ("ANI") (Nasdaq:ANIP) today announced the launch of Mexiletine Hydrochloride Capsules USP, 150mg, 200mg and 250mg. The current annual U.S. market for this product is approximately $16 million, according to IQVIA/IMS Health.
Jun 01, 2020 08:30 am ET
ANI Pharmaceuticals Provides Update on Recent Regulatory Filing
BAUDETTE, Minn., June 1, 2020 /PRNewswire/ -- ANI Pharmaceuticals, Inc. ("ANI") (NASDAQ: ANIP) announced today that it continues to make progress toward addressing items identified in the Refusal to File letter received from the FDA relating to its Cortrophin® Gel sNDA filing. 
May 07, 2020 08:30 am ET
Apr 30, 2020 08:30 am ET
ANI Pharmaceuticals Schedules Conference Call to Discuss First Quarter 2020 Financial Results
BAUDETTE, Minn., April 30, 2020 /PRNewswire/ -- ANI Pharmaceuticals, Inc. (NASDAQ: ANIP) announced today that the Company plans to release its first quarter 2020 financial results on Thursday, May 7, 2020, before the opening of the U.S. financial markets. The earnings press release will be accessible through the Investor Relations section of the Company's website, www.anipharmaceuticals.com.
Apr 29, 2020 08:30 am ET
ANI Receives Refusal to File Letter from FDA for Cortrophin® Gel
BAUDETTE, Minn., April 29, 2020 /PRNewswire/ -- ANI Pharmaceuticals, Inc. ("ANI") (Nasdaq: ANIP) today announced that it received a Refusal to File (RTF) letter from the U.S. Food and Drug Administration (FDA) regarding its supplemental new drug application (sNDA) for Cortrophin® Gel.  Upon its preliminary review, the FDA determined that certain portions of the Chemistry, Manufacturing and Controls section in the sNDA were not sufficiently complete to permit a substantive review.  ANI will seek immediate guidance, which potentially includes requesting a Type A meeting with the FDA, to clarif
Apr 14, 2020 08:30 am ET
ANI Announces Upcoming Departure of CEO
BAUDETTE, Minn., April 14, 2020 /PRNewswire/ -- ANI Pharmaceuticals, Inc. ("ANI") (Nasdaq: ANIP) today announced that Arthur S. Przybyl will depart as President and Chief Executive Officer on May 10, 2020. The Board of Directors has retained a nationally recognized executive search firm to lead the search for a new President and Chief Executive Officer.
Apr 13, 2020 08:30 am ET
ANI Announces FDA Acceptance of Supplemental Filing for Cortrophin® Gel 80 U/mL
BAUDETTE, Minn., April 13, 2020 /PRNewswire/ -- ANI Pharmaceuticals, Inc. ("ANI") (Nasdaq: ANIP) today announced that the U.S. Food & Drug Administration ("FDA") has accepted its supplemental new drug application ("sNDA") for Purified Cortrophin® Gel (Repository Corticotropin Injection USP) (80 U/mL).  The FDA set a PDUFA goal date of July 23, 2020.
Apr 02, 2020 08:30 am ET
ANI Pharmaceuticals Announces Launch of Omega-3-Acid Ethyl Esters Capsules USP
BAUDETTE, Minn., April 2, 2020 /PRNewswire/ -- ANI Pharmaceuticals, Inc. ("ANI") (Nasdaq: ANIP) today announced the launch of Omega-3-Acid Ethyl Esters Capsules USP, 1 gram.  The current annual U.S. market for this product is approximately $110 million, according to IQVIA/IMS Health.
Mar 26, 2020 08:30 am ET
ANI Announces Launch of Polyethylene Glycol 3350, 17g/Packet
BAUDETTE, Minn., March 26, 2020 /PRNewswire/ -- ANI Pharmaceuticals, Inc. ("ANI") (Nasdaq: ANIP) today announced the launch of Polyethylene Glycol 3350, 17g/Packet (PEG-3350). The current annual market for this over the counter (OTC) product is approximately $21 million, according to IQVIA.  This launch represents ANI's fourth new drug introduction in 2020.
Mar 24, 2020 11:00 am ET
ANI Pharmaceuticals Announces the Filing of a Prior Approval Supplement for Purified Cortrophin® Gel 80 U/mL
BAUDETTE, Minn., March 24, 2020 /PRNewswire/ -- ANI Pharmaceuticals, Inc. ("ANI") (Nasdaq: ANIP), an emerging leader in the specialty pharmaceutical industry, today announced that it has submitted a prior approval supplement (PAS) to the Endocrinology Division at the FDA for re-commercialization of Purified Cortrophin® Gel (Repository Corticotropin Injection USP) (80 U/mL).  The current annual market for Cortrophin® Gel is approximately $950 million and has only one competitor.  Cortrophin® Gel was originally approved by the FDA in 1954 and last used in patients in the 1980s.  Cortrophin® Ge
Mar 24, 2020 08:30 am ET
ANI Pharmaceuticals Announces the Filing of a Prior Approval Supplement for Purified Cortrophin® Gel 80 U/mL
BAUDETTE, Minn., March 24, 2020 /PRNewswire/ -- ANI Pharmaceuticals, Inc. ("ANI") (Nasdaq: ANIP), an emerging leader in the specialty pharmaceutical industry, today announced that it has submitted a prior approval supplement (PAS) to the Endocrinology Division at the FDA for re-commercialization of Purified Cortrophin® Gel (Repository Corticotropin Injection USP) (80 U/mL).  The current annual market for Cortrophin® Gel is approximately $950 million and has only one competitor.  Cortrophin® Gel was originally approved by the FDA in 1954 and last used in patients in the 1980s.  Cortrophin® Ge
Nov 06, 2019 07:30 am ET
ANI Pharmaceuticals Reports Third Quarter Results
BAUDETTE, Minn., Nov. 6, 2019 /PRNewswire/ --
Oct 31, 2019 08:30 am ET
ANI Announces Plans to Launch Bretylium Tosylate Injection, USP 500mg/10ml (50mg/ml) for Ventricular Arrhythmias
BAUDETTE, Minn., Oct. 31, 2019 /PRNewswire/ -- ANI Pharmaceuticals, Inc. ("ANI") (Nasdaq: ANIP) today announced that its partner Pharmaceutics International Inc. (Pii) has received FDA approval of a Prior Approval Supplement for Bretylium Tosylate Injection, USP 500mg/10ml (50mg/ml).  ANI plans to launch this currently unavailable drug in December, introducing this critical drug for the treatment of ventricular fibrillation and life-threatening ventricular arrhythmias, such as ventricular tachycardia.
Oct 30, 2019 08:30 am ET
ANI Pharmaceuticals Schedules Conference Call to Discuss Third Quarter and Year-to-Date 2019 Financial Results
BAUDETTE, Minn., Oct. 30, 2019 /PRNewswire/ -- ANI Pharmaceuticals, Inc. (NASDAQ: ANIP) announced today that the Company plans to release its third quarter and year-to-date 2019 financial results on Wednesday, November 6, 2019, before the opening of the U.S. financial markets. The earnings press release will be accessible through the Investor Relations section of the Company's website, www.anipharmaceuticals.com.
Oct 29, 2019 08:30 am ET
ANI Pharmaceuticals announces the launch of ANI Global Source, its contract development and manufacturing business
BAUDETTE, Minn., Oct. 29, 2019 /PRNewswire/ -- ANI Pharmaceuticals, Inc. ("ANI") (Nasdaq: ANIP), an experienced specialty pharmaceutical and contract development & manufacturing organization (CDMO), today announced the launch of its new CDMO brand, ANI Global Source.  This action follows the integration of WellSpring Pharma Services, acquired one year ago, and demonstrates the progress the company has made since the acquisition.  ANI Global Source is a specialty CDMO supporting late stage development and commercial manufacture of pharmaceutical products including tablets & capsules,
Oct 03, 2019 08:30 am ET
ANI Announces Positive Clinical Results from Cortrophin® Gel Cortisol Response Study
BAUDETTE, Minn., Oct. 3, 2019 /PRNewswire/ -- ANI Pharmaceuticals, Inc. ("ANI") (Nasdaq: ANIP) today announced the receipt of clinical data on Cortrophin® Gel (80 units/mL) from a study that evaluated the blood-level cortisol response in a 20-person healthy volunteer population. 
Oct 02, 2019 08:30 am ET
ANI Pharmaceuticals Announces Launch of Aspirin and Extended Release Dipyridamole Capsules, 25mg/200mg
BAUDETTE, Minn., Oct. 2, 2019 /PRNewswire/ -- ANI Pharmaceuticals, Inc. ("ANI") (Nasdaq: ANIP) today announced the launch of Aspirin and Extended Release Dipyridamole Capsules, 25mg/200mg (the generic equivalent of Aggrenox®).  This launch represents ANI's fifth generic product introduction in 2019.
Sep 11, 2019 08:30 am ET
ANI Pharmaceuticals Announces Launch of Vancomycin Hydrochloride for Oral Solution USP, 250mg/5mL
BAUDETTE, Minn., Sept. 11, 2019 /PRNewswire/ -- ANI Pharmaceuticals, Inc. ("ANI") (Nasdaq: ANIP) today announced the launch of Vancomycin HCl for Oral Solution, 250mg per 5mL (the generic equivalent to ANI's Vancocin® for Oral Solution).  To facilitate ease of administration the drug now includes a mixed berry taste, can be administered via nasogastric tube and does not contain any ingredients made with gluten-containing grain (wheat, barley, rye).  The dye-free product is delivered in a single bottle format requiring simple reconstitution and offers dosing flexibility achieved through the a
Aug 07, 2019 08:30 am ET
ANI Pharmaceuticals Reports Second Quarter Results
BAUDETTE, Minn., Aug. 7, 2019 /PRNewswire/ --
Jul 31, 2019 08:30 am ET
ANI Pharmaceuticals Schedules Conference Call to Discuss Second Quarter and Year-to-Date 2019 Financial Results
BAUDETTE, Minn., July 31, 2019 /PRNewswire/ -- ANI Pharmaceuticals, Inc. (NASDAQ: ANIP) announced today that the Company plans to release its second quarter and year-to-date 2019 financial results on Wednesday, August 7, 2019, before the opening of the U.S. financial markets. The earnings press release will be accessible through the Investor Relations section of the Company's website, www.anipharmaceuticals.com.
May 09, 2019 08:30 am ET
May 02, 2019 08:30 am ET
ANI Pharmaceuticals Schedules Conference Call to Discuss First Quarter 2019 Financial Results
BAUDETTE, Minn., May 2, 2019 /PRNewswire/ -- ANI Pharmaceuticals, Inc. (NASDAQ: ANIP) announced today that the Company plans to release its first quarter 2019 financial results on Thursday, May 9, 2019, before the opening of the U.S. financial markets. The earnings press release will be accessible through the Investor Relations section of the Company's website, www.anipharmaceuticals.com.
Apr 16, 2019 07:25 am ET
Investor Expectations to Drive Momentum within uniQure N.V., Aflac, ANI Pharmaceuticals, MaxLinear, ZAGG, and Aqua America — Discovering Underlying Factors of Influence
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of uniQure N.V. (NASDAQ:QURE), Aflac Incorporated (NYSE:AFL), ANI...
Apr 15, 2019 08:30 am ET
ANI Pharmaceuticals Expands Injectable Portfolio with Distribution Agreement for FDA Approved Injectable Product
BAUDETTE, Minn., April 15, 2019 /PRNewswire/ -- ANI Pharmaceuticals, Inc. ("ANI" or the "Company") (Nasdaq: ANIP) today announced that it has entered into a Distribution Agreement with a U.S. based injectable manufacturer to commercialize a unique specialty injectable product.  Key terms of the 10-year Agreement include cumulative milestones of up to $2M, payable by ANI. Upon launch, ANI will receive a 50% share of net profits generated from product revenues. The product, for which there are currently no other generics commercially available, recently received FDA approval. The product will
Mar 27, 2019 08:30 am ET
ANI Pharmaceuticals Announces Two Generic Product Launches
BAUDETTE, Minn., March 27, 2019 /PRNewswire/ -- ANI Pharmaceuticals, Inc. ("ANI" or the "Company") (Nasdaq: ANIP) today announced the launch of 18mg and 27mg Methylphenidate Hydrochloride Extended-Release Tablets, indicated as a treatment for Attention Deficit Hyperactivity Disorder ("ADHD"). The current annual U.S. market for these two strengths of the product is approximately $505 million, according to Iqvia.
Feb 27, 2019 07:30 am ET
Feb 20, 2019 07:30 am ET
ANI Pharmaceuticals Schedules Conference Call to Discuss Fourth Quarter and Year-to-Date 2018 Financial Results
BAUDETTE, Minn., Feb. 20, 2019 /PRNewswire/ -- ANI Pharmaceuticals, Inc. (NASDAQ: ANIP) announced today that the Company plans to release its fourth quarter and year-to-date 2018 financial results on Wednesday, February 27, 2019, before the opening of the U.S. financial markets. The earnings press release will be accessible through the Investor Relations section of the Company's website, www.anipharmaceuticals.com.
Feb 13, 2019 07:40 am ET
Factors of Influence in 2019, Key Indicators and Opportunity within Amkor Technology, U.S. Silica, Steven Madden, Rowan Companies, SunOpta, and ANI Pharmaceuticals — New Research Emphasizes Economic G
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Amkor Technology, Inc. (NASDAQ:AMKR), U.S. Silica Holdings, Inc....
Dec 27, 2018 03:30 pm ET
ANI Pharmaceuticals Secures Refinancing for Convertible Debt Due December 2019 and Enters Amended Five-Year $265 Million Senior Secured Credit Facility
BAUDETTE, Minn., Dec. 27, 2018 /PRNewswire/ -- ANI Pharmaceuticals, Inc. ("ANI" or the "Company") (Nasdaq: ANIP) today announced that it has entered an amended and restated five-year Senior Secured Credit Facility (the "Facility") for up to $265.2 million with its existing syndicate of bank lenders (the "Bank Group"). The Facility amends ANI's current $125 million Senior Secured Credit Facility and is structured to provide ANI flexibility in refinancing its 3.00% Convertible Senior Notes due 2019 ("the Convertible Notes"). The principal feature of the Facility is a new $118.0 million Delayed
Dec 07, 2018 07:00 am ET
ANI Pharmaceuticals Enters into Separate Privately Negotiated Agreements with Certain Holders of its Convertible Notes
BAUDETTE, Minn., Dec. 7, 2018 /PRNewswire/ -- (NASDAQ: ANIP) ANI Pharmaceuticals, Inc. (the "Company" or "ANI") today announced that it has entered into separate, privately negotiated agreements with certain holders of its outstanding 3.00% Convertible Senior Notes due 2019 (the "Notes"). ANI has agreed to repurchase $25.0 million aggregate principal amount of Notes for a total of $26.1 million in cash, including accrued but unpaid interest up to but excluding the closing date for the transactions.
Nov 15, 2018 08:15 am ET
ANI Pharmaceuticals, Inc. Ranked Number 366 Fastest Growing Company in North America on Deloitte's 2018 Technology Fast 500™
BAUDETTE, Minn., Nov. 15, 2018 /PRNewswire/ -- ANI Pharmaceuticals, Inc. ("ANI") (NASDAQ: ANIP) today announced it ranked No. 366 on Deloitte's Technology Fast 500™, a ranking of the 500 fastest growing technology, media, telecommunications, life sciences and energy tech companies in North America. ANI revenue grew 216% during this period.
Nov 12, 2018 07:25 am ET
Research Report Identifies Canopy Growth, MSG Networks, ANI Pharmaceuticals, Mistras Group, Rowan Companies, and Chemours with Renewed Outlook — Fundamental Analysis, Calculating Forward Movement
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Canopy Growth Corporation (NYSE:CGC), MSG Networks Inc. (NYSE:MSGN), ANI...
Nov 06, 2018 07:30 am ET
Oct 30, 2018 08:30 am ET
ANI Pharmaceuticals Schedules Conference Call to Discuss Third Quarter and Year-to-Date 2018 Financial Results
BAUDETTE, Minn., Oct. 30, 2018 /PRNewswire/ -- ANI Pharmaceuticals, Inc. (NASDAQ: ANIP) announced today that the Company plans to release its third quarter and year-to-date 2018 financial results on Tuesday, November 6, 2018, before the opening of the U.S. financial markets. The earnings press release will be accessible through the Investor Relations section of the Company's website, www.anipharmaceuticals.com.
Oct 18, 2018 09:00 am ET
Analysis: Positioning to Benefit within Clovis Oncology, Destination Maternity, MSG Networks, Lindblad Expeditions, NetScout, and ANI Pharmaceuticals — Research Highlights Growth, Revenue, and Consoli
In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Clovis Oncology, Inc. (NASDAQ:CLVS), Destination Maternity Corporation...
Oct 16, 2018 09:00 am ET
ANI Announces Launch of Authorized Generic of Brethine®
BAUDETTE, Minn., Oct. 16, 2018 /PRNewswire/ -- ANI Pharmaceuticals, Inc. ("ANI") (Nasdaq:ANIP) today announced the launch of Terbutaline Sulfate Tablets USP, 2.5mg and 5mg, an authorized generic of Brethine®. The current annual U.S. market for this product is approximately $11 million, according to Iqvia. Prior to ANI's launch there was only one supplier of the product in the U.S. market.
Oct 04, 2018 08:30 am ET
ANI Pharmaceuticals Announces Launch of Authorized Generic of Atacand HCT® Tablets
BAUDETTE, Minn., Oct. 4, 2018 /PRNewswire/ -- ANI Pharmaceuticals, Inc. ("ANI") (Nasdaq: ANIP) today announced the launch of Candesartan Hydrochlorothiazide Tablets, 16mg/12.5mg, 32mg/12.5mg, and 32mg/25mg, an authorized generic of Atacand HCT®.  The current annual U.S. market for this product is approximately $20 million, according to Iqvia/IMS Health.
Sep 27, 2018 08:30 am ET
ANI Pharmaceuticals to Present at the Cantor Fitzgerald Global Healthcare Conference
BAUDETTE, Minn., Sept. 27, 2018 /PRNewswire/ -- ANI Pharmaceuticals, Inc. (NASDAQ: ANIP) announced today that it will present on Wednesday, October 3, 2018 at 2:50 PM ET at the Cantor Fitzgerald Global Healthcare Conference in New York City. Arthur S. Przybyl, President and CEO and Stephen P. Carey, Vice President, Finance and CFO, will present on behalf of ANI Pharmaceuticals, Inc. The presentation will be webcast live at http://wsw.com/webcast/cantor7/anip/ and will be archived and available through the link through January 1, 2019.
Aug 27, 2018 07:45 am ET
Recent Analysis Shows KalVista Pharmaceuticals, IZEA, Sonic Automotive, Catabasis Pharmaceuticals, ANI Pharmaceuticals, and Clovis Oncology Market Influences — Renewed Outlook, Key Drivers of Growth
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV), IZEA Inc. (NASDAQ:IZEA),...
Aug 08, 2018 01:00 pm ET
ANI Pharmaceuticals to Present at New Time at the Canaccord Genuity 38th Annual Growth Conference
BAUDETTE, Minn., Aug. 8, 2018 /PRNewswire/ -- ANI Pharmaceuticals, Inc. (NASDAQ: ANIP) announced today that, due to a scheduling change at Canaccord Genuity, ANI will now present on Thursday, August 9, 2018 at 2:00 PM ET at the Canaccord Genuity 38th Annual Growth Conference. Arthur S. Przybyl, President and CEO and Stephen P. Carey, Vice President, Finance and CFO, will present on behalf of ANI Pharmaceuticals, Inc. The presentation will be webcast live at http://wsw.com/webcast/canaccord30/anip/ and will be archived and available through the link through November 7, 2018.
Aug 07, 2018 08:30 am ET
Aug 06, 2018 08:30 am ET
ANI Pharmaceuticals to Present at the Canaccord Genuity 38th Annual Growth Conference
BAUDETTE, Minn., Aug. 6, 2018 /PRNewswire/ -- ANI Pharmaceuticals, Inc. (NASDAQ: ANIP) announced today that it will present on Thursday, August 9, 2018 at 2:30 PM ET at the Canaccord Genuity 38th Annual Growth Conference. Arthur S. Przybyl, President and CEO and Stephen P. Carey, Vice President, Finance and CFO, will present on behalf of ANI Pharmaceuticals, Inc. The presentation will be webcast live at http://wsw.com/webcast/canaccord30/anip/ and will be archived and available through the link through November 7, 2018.
Aug 01, 2018 08:30 am ET
ANI Pharmaceuticals Schedules Conference Call to Discuss Second Quarter and Year-to-Date 2018 Financial Results
BAUDETTE, Minn., Aug. 1, 2018 /PRNewswire/ -- ANI Pharmaceuticals, Inc. (NASDAQ: ANIP) announced today that the Company plans to release its second quarter and year-to-date 2018 financial results on Tuesday, August 7, 2018, before the opening of the U.S. financial markets. The earnings press release will be accessible through the Investor Relations section of the Company's website, www.anipharmaceuticals.com.
Jun 27, 2018 08:00 am ET
ANI Pharmaceuticals Announces Launch of Cholestyramine for Oral Suspension USP
BAUDETTE, Minn., June 27, 2018 /PRNewswire/ -- ANI Pharmaceuticals, Inc. ("ANI") (Nasdaq: ANIP) today announced the launch of Cholestyramine for Oral Suspension USP, 4g/dose, in cans.  The current annual U.S. market for this product is approximately $22 million, according to Iqvia/IMS Health. 
Jun 25, 2018 07:50 am ET
Market Trends Toward New Normal in EnviroStar, Rowan Companies, Del Taco Restaurants, ANI Pharmaceuticals, Infinity Property and Casualty, and Viacom — Emerging Consolidated Expectations, Analyst Rati
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of EnviroStar, Inc. (NYSE:EVI), Rowan Companies PLC (NYSE:RDC), Del Taco...
Jun 05, 2018 08:30 am ET
ANI Shareholders Elect Three New Members to the Board of Directors
BAUDETTE, Minn., June 5, 2018 /PRNewswire/ -- ANI Pharmaceuticals, Inc. ("ANI") (NASDAQ: ANIP) today announced that the following three new members of the Board of Directors were elected at the Annual Meeting of Stockholders, held on May 17, 2018:
May 08, 2018 08:30 am ET
May 07, 2018 08:30 am ET
ANI Pharmaceuticals Completes Acquisition of Generic Products and Assets from Amneal/Impax
BAUDETTE, Minn., May 7, 2018 /PRNewswire/ -- ANI Pharmaceuticals, Inc. ("ANI") (Nasdaq: ANIP) today announced that it has completed the acquisition of a portfolio of six generic products, related manufacturing and supply agreements, and equipment and technical know-how from Amneal Pharmaceuticals, LLC and Impax Laboratories, Inc. (NASDAQ: IPXL) for cash consideration of $2.3 million.  The portfolio of generic products has a combined current annual U.S. market of $1.7 billion according to Iqvia/IMS Health. 
May 07, 2018 07:55 am ET
Market Trends Toward New Normal in Viacom, Nutanix, ANI Pharmaceuticals, PACCAR, Cabot Oil & Gas, and Box — Emerging Consolidated Expectations, Analyst Ratings
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Viacom Inc. (NASDAQ:VIAB), Nutanix Inc. (NASDAQ:NTNX), ANI...
May 01, 2018 08:30 am ET
ANI Pharmaceuticals Schedules Conference Call to Discuss First Quarter 2018 Financial Results
BAUDETTE, Minn., May 1, 2018 /PRNewswire/ -- ANI Pharmaceuticals, Inc. (NASDAQ: ANIP) announced today that the Company plans to release its first quarter 2018 financial results on Tuesday, May 8, 2018, before the opening of the U.S. financial markets. The earnings press release will be accessible through the Investor Relations section of the Company's website, www.anipharmaceuticals.com.
Apr 27, 2018 06:50 pm ET
Amneal And Impax Receive FTC Clearance For Business Combination
BRIDGEWATER, N.J., April 27, 2018 /PRNewswire/ -- Amneal Pharmaceuticals LLC and Impax Laboratories, Inc. (NASDAQ: IPXL) today announced that the U.S. Federal Trade Commission (FTC) has cleared the Amneal and Impax business combination, subject to Amneal and Impax's agreement to divest certain products.
Apr 27, 2018 06:30 pm ET
ANI Pharmaceuticals Signs Definitive Agreements to Acquire Generic Products and Assets from Amneal/Impax
BAUDETTE, Minn., April 27, 2018 /PRNewswire/ -- ANI Pharmaceuticals, Inc. ("ANI") (Nasdaq: ANIP) today announced that it has signed definitive agreements to acquire a portfolio of generic products and other assets from Amneal Pharmaceuticals, LLC and Impax Laboratories, Inc. (NASDAQ:IPXL) for undisclosed cash consideration.  The transaction is the result of a divestiture process mandated by the Federal Trade Commission ("FTC") in connection with Amneal Pharmaceutical's proposed business combination with Impax Laboratories.  The parties expect to close the transaction in early May.
Apr 18, 2018 08:30 am ET
ANI Pharmaceuticals Announces Approval of Morphine Sulfate Oral Solution
BAUDETTE, Minn., April 18, 2018 /PRNewswire/ -- ANI Pharmaceuticals, Inc. ("ANI") (Nasdaq: ANIP) today announced that it has received approval from the U.S. Food and Drug Administration ("FDA") of its Abbreviated New Drug Application ("ANDA") for Morphine Sulfate Oral Solution 10mg/5mL, 20mg/5mL and 100mg/5mL. The current annual U.S. market for this product is approximately $17 million, according to Iqvia/IMS Health. ANI expects to begin shipping product to its customers in the near future.
Apr 04, 2018 08:30 am ET
ANI Acquires 23 ANDAs from IDT Australia, Ltd.
BAUDETTE, Minn., April 4, 2018 /PRNewswire/ -- ANI Pharmaceuticals, Inc. ("ANI") (Nasdaq: ANIP) today announced that it has acquired ANDAs for 23 previously marketed generic drug products from IDT Australia, Ltd. ("IDT") for $2.6 million and a limited single-digit royalty for one product. Additionally, ANI acquired active pharmaceutical ingredient for one of the acquired products for $135 thousand. In 2015, ANI had secured the U.S. licensing rights and 40% to 50% of the net profits upon commercialization for these products from IDT for $1.0 million. Today's acquisition gives ANI full control
Mar 05, 2018 07:35 am ET
Detailed Research: Economic Perspectives on Lear, MYOS RENS Technology, Dollar Tree, Halliburton, Waters, and ANI Pharmaceuticals — What Drives Growth in Today's Competitive Landscape
NEW YORK, March 05, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Lear Corporation (NYSE:LEA), MYOS RENS Technology...
Mar 02, 2018 07:30 am ET
ANI Pharmaceuticals to Present at the Raymond James 39th Annual Institutional Investors Conference
BAUDETTE, Minn., March 2, 2018 /PRNewswire/ -- ANI Pharmaceuticals, Inc. (NASDAQ: ANIP) announced today that it will present on Wednesday, March 7, 2018 at 11:35 AM ET at the Raymond James 39th Annual Institutional Investors Conference. Arthur S. Przybyl, President and CEO, will present on behalf of ANI Pharmaceuticals, Inc. Stephen P. Carey, Vice President, Finance and CFO, will also be in attendance and representing ANI.
Feb 27, 2018 09:00 am ET
ANI Pharmaceuticals, Inc. to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / February 27, 2018 / ANI Pharmaceuticals, Inc. (NASDAQ: ANIP) will be discussing their earnings results in their Q4 Earnings Call to be held on February 27, 2018 at 10:30 AM Eastern Time.
Feb 20, 2018 07:30 am ET
ANI Pharmaceuticals Schedules Conference Call to Discuss Fourth Quarter and Full Year 2017 Financial Results and 2018 Guidance
BAUDETTE, Minn., Feb. 20, 2018 /PRNewswire/ -- ANI Pharmaceuticals, Inc. (NASDAQ: ANIP) announced today that the Company plans to release its fourth quarter and full year 2017 financial results and 2018 guidance on Tuesday, February 27, 2018, before the opening of the U.S. financial markets. The earnings press release will be accessible through the Investor Relations section of the Company's website, www.anipharmaceuticals.com.
Dec 29, 2017 08:26 am ET
ANI Pharmaceuticals Enters Five-Year $125 Million Senior Secured Credit Facility with Citizens Bank
BAUDETTE, Minn., Dec. 29, 2017 /PRNewswire/ -- ANI Pharmaceuticals, Inc. ("ANI") (Nasdaq: ANIP) today announced that it has entered a new five-year Senior Secured Credit Facility (the "Facility") for up to $125 million with Citizens Bank. The Facility is comprised of a $75 million five-year term loan that was closed today in support of ANI's acquisition of four NDAs acquired from AstraZeneca for $46.5 million in cash as previously announced this morning.  In addition, the term loan has been utilized to refinance existing indebtedness of $25 million that was outstanding against ANI's now reti
Dec 29, 2017 08:21 am ET
ANI Pharmaceuticals Acquires Four NDAs from AstraZeneca for $46.5 Million
BAUDETTE, Minn., Dec. 29, 2017 /PRNewswire/ -- ANI Pharmaceuticals, Inc. ("ANI") (Nasdaq: ANIP) today announced that it has acquired the NDAs and U.S. rights to market ATACAND®, ATACAND HCT®, ARIMIDEX®, and CASODEX® from AstraZeneca for $46.5 million in cash, royalties, and sales-based milestones.  AstraZeneca will continue to market and supply ATACAND®, ATACAND HCT®, ARIMIDEX®, and CASODEX® outside of the U.S. The acquired assets include the NDAs for all four products and a license to their trademarks.  The acquisitions were funded through a combination of cash and debt.
Nov 02, 2017 09:30 am ET
Nov 02, 2017 08:30 am ET
Report: Developing Opportunities within Echelon, NII Holdings, ANI Pharmaceuticals, Zion Oil & Gas, vTv Therapeutics, and Sears Holdings – Future Expectations, Projections Moving into 2018
NEW YORK, Nov. 02, 2017 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Echelon Corporation (NASDAQ:ELON), NII Holdings, Inc....
Oct 26, 2017 09:30 am ET
ANI Pharmaceuticals Schedules Conference Call to Discuss Third Quarter and Year-to-Date 2017 Financial Results
BAUDETTE, Minn., Oct. 26, 2017 /PRNewswire/ -- ANI Pharmaceuticals, Inc. (NASDAQ: ANIP) announced today that the Company plans to release its third quarter and year-to-date 2017 financial results on Thursday, November 2, 2017, before the opening of the U.S. financial markets. The earnings press release will be accessible through the Investor Relations section of the Company's website, www.anipharmaceuticals.com.
Sep 01, 2017 09:30 am ET
ANI Pharmaceuticals Announces Approval and Launch of Oxycodone Hydrochloride Oral Solution, 100 mg/5mL
BAUDETTE, Minn., Sept. 1, 2017 /PRNewswire/ -- ANI Pharmaceuticals, Inc. ("ANI") (Nasdaq: ANIP) today announced that it has received approval from the U.S. Food and Drug Administration ("FDA") of its Abbreviated New Drug Application ("ANDA") for Oxycodone Hydrochloride Oral Solution USP, 100 mg/5 mL (20 mg/mL). The current annual U.S. market for this product is approximately $14.5 million, according to IMS Health. ANI expects to begin shipping to its customers immediately.
Aug 08, 2017 09:30 am ET
ANI Pharmaceuticals to Present at the Canaccord Genuity 37th Annual Growth Conference
BAUDETTE, Minn, Aug. 8, 2017 /PRNewswire/ -- ANI Pharmaceuticals, Inc. (NASDAQ: ANIP) announced today that it will present on Wednesday, August 9, 2017 at 4:30 PM ET at the Canaccord Genuity 37th Annual Growth Conference. Arthur S. Przybyl, President and CEO and Stephen P. Carey, Vice President, Finance and CFO, will present on behalf of ANI Pharmaceuticals, Inc. The presentation will be webcast live at http://wsw.com/webcast/canaccord26/anip, and will be archived and available through the link through November 7, 2017.
Aug 03, 2017 09:30 am ET
Jul 27, 2017 09:30 am ET
ANI Pharmaceuticals Schedules Conference Call to Discuss Second Quarter and Year-to-Date 2017 Financial Results
BAUDETTE, Minn., July 27, 2017 /PRNewswire/ -- ANI Pharmaceuticals, Inc. (NASDAQ: ANIP) announced today that the Company plans to release its second quarter and year-to-date 2017 financial results on Thursday, August 3, 2017, before the opening of the U.S. financial markets. The earnings press release will be accessible through the Investor Relations section of the Company's website, www.anipharmaceuticals.com.
Jul 26, 2017 10:31 am ET
Options trade ideas for ANI Pharmaceuticals, Facebook, Gilead Sciences, Hilton Worldwide and Shutterfly offer returns of 21% or more!
CHICAGO, July 26, 2017 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ANIP, FB, GILD, HLT, and SFLY.
Jun 20, 2017 09:30 am ET
ANI Pharmaceuticals Announces Launch of Diphenoxylate HCl and Atropine Sulfate Tablets
BAUDETTE, Minn., June 20, 2017 /PRNewswire/ -- ANI Pharmaceuticals, Inc. ("ANI") (Nasdaq: ANIP) today announced the launch of Diphenoxylate HCl and Atropine Sulfate Tablets, 2.5mg/0.025mg.  The annual U.S. market for Diphenoxylate HCl and Atropine Sulfate Tablets is approximately $56 million, per IMS Health.  Prior to ANI's launch there were two companies marketing a generic version of this drug product.
May 08, 2017 10:15 am ET
ANI Pharmaceuticals Announces Launch of Pindolol Tablets
BAUDETTE, Minn., May 8, 2017 /PRNewswire/ -- ANI Pharmaceuticals, Inc. ("ANI") (Nasdaq: ANIP) today announced the launch of Pindolol Tablets, 5mg and 10mg, which is used in the treatment of hypertension. The annual U.S. market for Pindolol Tablets is approximately $10 million, per IMS Health.
May 04, 2017 09:30 am ET
Apr 27, 2017 09:30 am ET
ANI Pharmaceuticals Schedules Conference Call to Discuss First Quarter 2017 Financial Results
BAUDETTE, Minn., April 27, 2017 /PRNewswire/ -- ANI Pharmaceuticals, Inc. (NASDAQ: ANIP) announced today that the Company plans to release its first quarter 2017 financial results on Thursday, May 4, 2017, before the opening of the U.S. financial markets. The earnings press release will be accessible through the Investor Relations section of the Company's website, www.anipharmaceuticals.com.
Apr 19, 2017 09:30 am ET
ANI Pharmaceuticals Announces Launch of Indapamide Tablets
BAUDETTE, Minn., April 19, 2017 /PRNewswire/ -- ANI Pharmaceuticals, Inc. ("ANI") (Nasdaq: ANIP) today announced launch of Indapamide Tablets, 1.25mg and 2.5mg, which is used in the treatment of hypertension and swelling associated with congestive heart failure. The annual U.S. market for Indapamide Tablets is approximately $9 million, per IMS Health.
Mar 02, 2017 08:30 am ET
Feb 24, 2017 08:30 am ET
ANI Pharmaceuticals Acquires Inderal® XL and InnoPran XL®
BAUDETTE, Minn., Feb. 24, 2017 /PRNewswire/ -- ANI Pharmaceuticals, Inc. ("ANI") (Nasdaq: ANIP) today announced that it has acquired Inderal® XL from Cranford Pharmaceuticals, LLC and InnoPran XL®  from Holmdel Pharmaceuticals LP.  The acquired assets include the NDA and trademark for InnoPran XL® including a license to an Orange Book listed patent, and a distribution license and trademark for Inderal® XL as well as finished goods inventory of both products.  Inderal® XL and InnoPran XL® are currently available in 80mg and 120mg sustained release capsules and are indicated for hypertension. 
Feb 16, 2017 08:30 am ET
ANI Pharmaceuticals Schedules Conference Call for Fourth Quarter and Full Year 2016 Financial Results and 2017 Guidance
BAUDETTE, Minn., Feb. 16, 2017 /PRNewswire/ -- ANI Pharmaceuticals, Inc. (NASDAQ: ANIP) announced today that the Company plans to release its fourth quarter and full year 2016 financial results and 2017 guidance on Thursday, March 2, 2017, before the opening of the U.S. financial markets. The earnings press release will be accessible through the Investor Relations section of the Company's website, www.anipharmaceuticals.com.
Jan 17, 2017 08:30 am ET
ANI Announces Appointment of Karen Quinn Ph.D as Vice President Corticotropin Regulatory Affairs
BAUDETTE, Minn., Jan. 17, 2017 /PRNewswire/ -- ANI Pharmaceuticals, Inc. ("ANI") (Nasdaq: ANIP) today announced the appointment of Karen Quinn Ph.D as Vice President Corticotropin Regulatory Affairs, effective January 17, 2017. 
Dec 21, 2016 08:30 am ET
ANI Pharmaceuticals Announces Launch of Authorized Generic of Lithobid® Extended Release Tablets
BAUDETTE, Minn., Dec. 21, 2016 /PRNewswire/ -- ANI Pharmaceuticals, Inc. ("ANI") (Nasdaq: ANIP) today announced the launch of Lithium Carbonate Extended Release Tablets, 300mg, an authorized generic of Lithobid®, which is used in the treatment of manic episodes of Bipolar Disorder. The annual US market for lithium carbonate is approximately $19 million, per IMS Health.
Dec 20, 2016 08:30 am ET
ANI Pharmaceuticals Announces Launch of Vancomycin Capsules in 50 Count Bottle
BAUDETTE, Minnesota, Dec. 20, 2016 /PRNewswire/ -- ANI Pharmaceuticals, Inc. ("ANI") (Nasdaq: ANIP) today announced the launch of Vancomycin HCl 125mg and 250mg capsules, indicated for treatment of C. difficile-associated diarrhea, in a fifty count bottle.  The fifty count bottle of Vancomycin HCl capsules accounts for approximately 40% of the Vancomycin capsule volume and the annual US market for this bottle configuration is approximately $21 million, per IMS Health.
Nov 03, 2016 09:30 am ET
ANI Pharmaceuticals Reports Record Third Quarter Results and Year-To-Date 2016 Highlights and Narrows Full-year Guidance
BAUDETTE, Minn., Nov. 3, 2016 /PRNewswire/ -- ANI Pharmaceuticals, Inc. ("ANI") (NASDAQ: ANIP) today reported record financial results for the three and nine months ended September 30, 2016, and reaffirmed and narrowed its 2016 financial guidance. The Company will host its earnings conference call this morning, November 3, 2016, at 10:30 AM ET. Investors and other interested parties can join the call by dialing (866) 776-8875. The conference ID is 93840986.
Oct 27, 2016 09:30 am ET
ANI Pharmaceuticals Schedules Conference Call to Discuss Third Quarter and Year-to-Date 2016 Financial Results
BAUDETTE, Minn., Oct. 27, 2016 /PRNewswire/ -- ANI Pharmaceuticals, Inc. (NASDAQ: ANIP) announced today that the Company plans to release its third quarter and year-to-date 2016 financial results on Thursday, November 3, 2016, before the opening of the U.S. financial markets. The earnings press release will be accessible through the Investor Relations section of the Company's website, www.anipharmaceuticals.com.
Oct 25, 2016 09:30 am ET
ANI Pharmaceuticals Announces Launch of Benztropine Mesylate Tablets USP
BAUDETTE, Minn., Oct. 25, 2016 /PRNewswire/ -- ANI Pharmaceuticals, Inc. ("ANI") (Nasdaq: ANIP) today announced the launch of Benztropine Mesylate Tablets USP 0.5 mg, 1 mg and 2 mg. The current annual U.S. market for this product is approximately $25 million, according to IMS Health. ANI will immediately launch the product.
Sep 27, 2016 09:30 am ET
ANI Pharmaceuticals Announces Launch of Erythromycin Ethylsuccinate for Oral Suspension, 200mg/5mL
BAUDETTE, Minn., Sept. 27, 2016 /PRNewswire/ -- ANI Pharmaceuticals, Inc. ("ANI") (Nasdaq: ANIP) today announced the launch of Erythromycin Ethylsuccinate for Oral Suspension 200mg/5mL indicated as a treatment for various infections.  The current annual U.S. market for this product is approximately $78 million, according to IMS Health, and is representative of two brand products.  ANI will immediately launch the product.
Aug 04, 2016 09:30 am ET
ANI Pharmaceuticals Reports Record Second Quarter Results and Increases Full-year 2016 Guidance
BAUDETTE, Minn., Aug. 4, 2016 /PRNewswire/ -- ANI Pharmaceuticals, Inc. ("ANI") (NASDAQ: ANIP) today reported financial results for the three and six months ended June 30, 2016, and increased its financial guidance for 2016. The Company will host its earnings conference call this morning, August 4, 2016, at 10:30 AM ET. Investors and other interested parties can join the call by dialing (866) 776-8875. The conference ID is 47510730.
Jul 28, 2016 09:30 am ET
ANI Pharmaceuticals Schedules Conference Call to Discuss Second Quarter and Year-to-Date 2016 Financial Results
BAUDETTE, Minn., July 28, 2016 /PRNewswire/ -- ANI Pharmaceuticals, Inc. (NASDAQ: ANIP) announced today that the Company plans to release its second quarter and year-to-date 2016 financial results on Thursday, August 4, 2016, before the opening of the U.S. financial markets. The earnings press release will be accessible through the Investor Relations section of the Company's website, www.anipharmaceuticals.com.
Jul 18, 2016 09:30 am ET
ANI Pharmaceuticals Announces FDA Approval and Immediate Launch of Nilutamide Tablets, the First Generic Competitor to Nilandron®
BAUDETTE, Minn., July 18, 2016 /PRNewswire/ -- ANI Pharmaceuticals, Inc. ("ANI") (Nasdaq: ANIP) today announced that it has received approval from the U.S. Food and Drug Administration ("FDA") of the Abbreviated New Drug Application ("ANDA") for nilutamide tablets.  Trailing twelve-month sales of Nilandron® were $23 million according to IMS Health.  ANI will immediately launch the product.
Jun 28, 2016 09:30 am ET
ANI Pharmaceuticals Announces Launch of Hydroxyprogesterone Caproate Injection USP, 250mg/mL
BAUDETTE, Minn., June 28, 2016 /PRNewswire/ -- ANI Pharmaceuticals, Inc. ("ANI") (Nasdaq: ANIP) today announced the commercial launch of Hydroxyprogesterone Caproate Injection ("HPC") USP 250mg/mL in 5mL vials.
Jun 13, 2016 09:05 am ET
ANI Pharmaceuticals Announces FDA Approval of Oxcarbazepine Tablets
BAUDETTE, Minn., June 13, 2016 /PRNewswire/ -- ANI Pharmaceuticals, Inc. ("ANI") (Nasdaq: ANIP) today announced that it has received approval from the U.S. Food and Drug Administration ("FDA") of the Prior Approval Supplement ("PAS") for Oxcarbazepine Tablets, 150mg, 300mg and 600mg.  The current annual U.S. market for this product, based on trailing twelve months sales, is $145 million according to IMS Health.
Jun 13, 2016 09:00 am ET
ANI Pharmaceuticals Announces Launch of Oxycodone Capsules, 5mg
BAUDETTE, Minn., June 13, 2016 /PRNewswire/ -- ANI Pharmaceuticals, Inc. ("ANI") (Nasdaq: ANIP) today announced the commercial launch of Oxycodone HCl Capsules, 5mg.  Trailing twelve-month sales for the product are $7.5 million according to IMS Health.
May 23, 2016 09:30 am ET
ANI Announces Appointment of Mark J. Ginski Ph.D as Vice President Corticotropin Product Development
BAUDETTE, Minn., May 23, 2016 /PRNewswire/ -- ANI Pharmaceuticals, Inc. ("ANI") (Nasdaq: ANIP) today announced the appointment of Mark Ginski Ph.D as Vice President Corticotropin Product Development, effective May 23, 2016. 
May 18, 2016 09:00 am ET
ANI Pharmaceuticals to Present at the UBS Global Healthcare Conference
BAUDETTE, Minn., May 18, 2016 /PRNewswire/ -- ANI Pharmaceuticals, Inc. (NASDAQ: ANIP) announced today that it will present on May 23, 2016 at the UBS Global Healthcare Conference at the Grand Hyatt in New York City. On Monday, May 23, 2016 at 2:00 PM ET, Arthur S. Przybyl, President and CEO, will give the Company's presentation, which is posted on the Investor section of ANI's website at www.anipharmaceuticals.com. The presentation will be webcast live at https://cc.talkpoint.com/ubsx001/052316a_ae/?entity=62_R53VV6X, and will be archived and available through the link through August 21, 20
May 17, 2016 10:00 am ET
ANI Pharmaceuticals Enters Into Exclusive Distribution and Supply Agreement for Hydroxyprogesterone Caproate Injection USP
BAUDETTE, Minn., May 17, 2016 /PRNewswire/ -- ANI Pharmaceuticals, Inc. ("ANI") (Nasdaq: ANIP) today announced the signing of an exclusive distribution and supply agreement with Aspen Global Incorporated for Hydroxyprogesterone Caproate Injection ("HPC") USP 250mg/mL in 5mL vials.  Aspen will be responsible for supplying the finished goods and ANI Pharmaceuticals will be responsible for marketing and distribution in the U.S.  Aspen's product was approved by FDA in August 2015 (ANDA# 200271) and ANI intends to commercialize HPC in the near term. For product inquiries, please contact ANI at 21
May 16, 2016 10:15 am ET
ANI Pharmaceuticals Launches Authorized Generic of Rowasa® Enema 4g/60mL
BAUDETTE, Minn., May 16, 2016 /PRNewswire/ -- ANI Pharmaceuticals, Inc. ("ANI") (Nasdaq: ANIP) today announced the commercial launch of authorized generic Rowasa® (mesalamine) rectal suspension enema 4g/60ml in a 7x60ml carton.  According to IMS Health, sales for generic mesalamine rectal suspension enema 4g/60ml were $20.5 million, on a trailing twelve month basis.
May 13, 2016 10:00 am ET
ANI Pharmaceuticals Enters Three Year $30 Million Asset Based Line of Credit with Citizens Bank
BAUDETTE, Minnesota, May 13, 2016 /PRNewswire/ -- ANI Pharmaceuticals, Inc. ("ANI") (Nasdaq: ANIP) today announced that it has entered a new three year senior secured asset-based revolving credit facility for up to $30 million. This facility will be secured by inventory and certain other working capital and related assets of ANI Pharmaceuticals, Inc.
May 09, 2016 09:00 am ET
ANI Pharmaceuticals Announces Launch of 50mg and 150mg Fenofibrate Capsules in ANI label
BAUDETTE, Minn., May 9, 2016 /PRNewswire/ -- ANI Pharmaceuticals, Inc. ("ANI") (Nasdaq: ANIP) today announced the commercial launch of 50mg and 150mg fenofibrate capsules USP (the authorized generic of Lipofen®) in the ANI label.  The distribution rights to fenofibrate were acquired earlier this year and, as previously announced, ANI had expected to transition these products to the ANI label in the second quarter of 2016. In 2015 the authorized generic for Lipofen® (fenofibrate capsules 50mg and 150mg USP) generated $21.9 million in revenues. 
May 05, 2016 09:00 am ET
ANI Pharmaceuticals Reports First Quarter Results and Year-To-Date 2016 Highlights and Reaffirms Updated Guidance
BAUDETTE, Minn., May 5, 2016 /PRNewswire/ -- ANI Pharmaceuticals, Inc. ("ANI") (NASDAQ: ANIP) today reported financial results for the three months ended March 31, 2016, and reaffirmed its financial guidance for 2016 as updated on April 4, 2016. The Company will host its earnings conference call this morning, May 5, 2016, at 10:30 AM ET. Investors and other interested parties can join the call by dialing (844) 295-8236. The conference ID is 93601942.
Apr 27, 2016 09:05 am ET
ANI Pharmaceuticals Schedules Conference Call to Discuss First Quarter 2016 Financial Results and Reaffirm Guidance
BAUDETTE, Minn., April 27, 2016 /PRNewswire/ -- ANI Pharmaceuticals, Inc. (NASDAQ: ANIP) announced today that the Company plans to release its first quarter 2016 financial results and reaffirm guidance on Thursday, May 5, 2016, before the opening of the U.S. financial markets. The earnings press release will be accessible through the Investor Relations section of the Company's website, www.anipharmaceuticals.com.
Apr 27, 2016 09:00 am ET
ANI Announces Appointment of Stephen P. Carey as Vice President and Chief Financial Officer
BAUDETTE, Minn., April 27, 2016 /PRNewswire/ -- ANI Pharmaceuticals, Inc. ("ANI") (Nasdaq: ANIP) today announced the appointment of Stephen P. Carey to the position of Vice President and Chief Financial Officer, effective May 6, 2016.
Apr 05, 2016 09:05 am ET
ANI Pharmaceuticals Announces FDA Approval of Oxycodone Capsules, 5mg
BAUDETTE, Minn., April 5, 2016 /PRNewswire/ -- ANI Pharmaceuticals, Inc. ("ANI") (Nasdaq: ANIP) today announced that it has received approval from the U.S. Food and Drug Administration ("FDA") of the Abbreviated New Drug Application ("ANDA") for Oxycodone HCl Capsules, 5mg.  Trailing twelve-month sales for the product are $7.5 million according to IMS Health.
Apr 05, 2016 09:00 am ET
ANI Pharmaceuticals Announces Launch of Hydrocortisone Rectal Cream 1% and 2.5%
BAUDETTE, Minn., April 5, 2016 /PRNewswire/ -- ANI Pharmaceuticals, Inc. ("ANI") (Nasdaq: ANIP) today announced the commercial launch of 1% and 2.5% hydrocortisone cream for rectal use.  The combined market for these products was $84 million over the trailing twelve months through February 2016, according to IMS Health. 
Apr 04, 2016 09:05 am ET
ANI Pharmaceuticals Updates 2016 Financial Guidance
BAUDETTE, Minn., April 4, 2016 /PRNewswire/ -- As a result of the close of the acquisition of the Inderal® LA assets from Cranford Pharmaceuticals, ANI Pharmaceuticals, Inc. ("ANI") (Nasdaq: ANIP) today issued revised financial guidance for 2016.
Apr 04, 2016 09:00 am ET
ANI Pharmaceuticals Closes Acquisition of Inderal® LA Assets
BAUDETTE, Minn., April 4, 2016 /PRNewswire/ -- ANI Pharmaceuticals, Inc. ("ANI") (Nasdaq: ANIP) today announced that it has completed the acquisition of the portfolio of Inderal® LA assets from Cranford Pharmaceuticals, LLC.  As previously communicated, the acquired portfolio includes the NDA and trademark for Inderal® LA as well as finished goods inventory.  The acquisition was funded through cash on hand.
Mar 11, 2016 08:00 am ET
ANI Pharmaceuticals Agrees to Acquire Inderal® LA Assets from Cranford Pharmaceuticals
BAUDETTE, Minn., March 11, 2016 /PRNewswire/ -- ANI Pharmaceuticals, Inc. ("ANI") (Nasdaq: ANIP) today announced that it has agreed to acquire a portfolio of Inderal® LA assets from Cranford Pharmaceuticals, LLC. The acquired portfolio will include the NDA and trademark for Inderal® LA as well as finished goods inventory. Cranford Pharmaceuticals, LLC owns the NDA for Inderal® LA 60mg, 80mg, 120mg and 160mg sustained release capsules as well as the authorized generic, propranolol ER capsules, both of which are indicated for hypertension, angina pectoris, migraine and hypertrophic subaortic s

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.